| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 71 nM (dopamine uptake)[1]
AHN 1-055 binds with high affinity to the dopamine transporter (DAT). It inhibits dopamine uptake with an IC50 of 71 nM. The compound also interacts with sigma receptors (σR) in vivo. Its ability to modulate dopamine levels makes it valuable for studying dopamine-related disorders. |
|---|---|
| ln Vitro |
In cell-free binding assays, AHN 1-055 demonstrates high-affinity binding to the dopamine transporter. The compound effectively displaces radiolabeled DAT ligands, confirming its interaction with the transporter binding site. It shows potent inhibition of dopamine uptake in synaptosomal preparations with an IC50 of 71 nM. The binding affinity is consistent with its tropane-like structure. In cellular uptake assays using cells expressing the dopamine transporter, AHN 1-055 potently inhibits [³H]dopamine uptake with an IC50 of 71 nM. The compound demonstrates concentration-dependent inhibition of DAT-mediated dopamine transport. It is capable of crossing the blood-brain barrier in cellular models, confirming its suitability for CNS research.
|
| ln Vivo |
AHN 1-055 (5 mg/kg; intravenous administration) inhibits the absorption of dopamine in the brain, with an in vivo IC50 of 311.8 ng/ml[1]. Because of its 18.7 L/kg volume of distribution and 1.8 L/h/kg plasma clearance, AHN 1-055 (10 mg/kg; i.v.) has a terminal elimination half-life of 7.69 hours and a Cmax of 1.48 mg/L[1].
In vivo, AHN 1-055 has been shown to antagonize cocaine self-administration in rat models. A higher dose of AHN 1-055 completely suppresses cocaine-maintained responding. The compound dose-dependently decreases cocaine self-administration. It functions as a sigma receptor antagonist in vivo, and its effects on cocaine self-administration are mediated through both DAT and sigma receptor interactions. |
| Enzyme Assay |
Dopamine transporter binding assays are performed using membrane preparations from cells or tissues expressing DAT. Radioligand binding studies use [³H]WIN 35,428 or [³H]CFT as the labeled ligand. Membranes are incubated with varying concentrations of AHN 1-055 and the radioligand, followed by filtration and scintillation counting. IC50 values are calculated from competition binding curves.
|
| Cell Assay |
Dopamine uptake inhibition assays are conducted using cells expressing the human dopamine transporter or using rat brain synaptosomes. Cells are pre-incubated with AHN 1-055 at various concentrations, then [³H]dopamine is added. Uptake is terminated after a defined period by rapid filtration, and accumulated radioactivity is measured by scintillation counting. IC50 values are determined from concentration-response curves.
|
| Animal Protocol |
Animal/Disease Models: Adult male Sprague Dawley rats (250-275 g)[1]
Doses: 5 mg/kg (pharmacokinetic/PK Analysis) Route of Administration: Iv administration Experimental Results: Cmax (1.48 mg/L); T1/2 (7.69 h). |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of AHN 1-055 have been characterized in rodent models. The compound is capable of crossing the blood-brain barrier, achieving sufficient CNS concentrations to modulate dopamine levels. The benztropine scaffold provides favorable brain penetration characteristics. Detailed PK parameters including half-life and bioavailability remain to be fully characterized in published literature.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for AHN 1-055 are limited, as the compound is primarily used as a research tool. In animal studies, the compound is administered at doses ranging from 10-32 mg/kg without significant adverse effects reported. The compound does not display a cocaine-like behavioral profile despite its ability to inhibit dopamine uptake, suggesting a favorable safety profile relative to cocaine.
|
| References |
[1]. Sangeeta R, et, al. Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. Biopharm Drug Dispos. 2006 Jul; 27(5): 229-40.
|
| Additional Infomation |
AHN 1-055 is a benztropine analog investigated for the treatment of cocaine abuse. Studies have confirmed its antagonism of cocaine self-administration in rats. The compound's dual action at DAT and sigma receptors contributes to its unique pharmacological profile. AHN 1-055 is a valuable tool for understanding the mechanisms underlying stimulant use disorders.
|
| Molecular Formula |
C21H24CLF2NO
|
|---|---|
| Molecular Weight |
379.87
|
| Exact Mass |
379.151
|
| CAS # |
202646-03-5
|
| PubChem CID |
24978533
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
396
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
Cl.FC1=CC=C(C(C2=CC=C(F)C=C2)OC2CC3CCC(N3C)C2)C=C1
|
| InChi Key |
YOORVSGDAHWVMC-IIPFOPBBSA-N
|
| InChi Code |
InChI=1S/C21H23F2NO.ClH/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15;/h2-9,18-21H,10-13H2,1H3;1H/t18-,19+,20?;
|
| Chemical Name |
(1R,5S)-3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (263.25 mM)
H2O: 33.33 mg/mL (87.74 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6325 mL | 13.1624 mL | 26.3248 mL | |
| 5 mM | 0.5265 mL | 2.6325 mL | 5.2650 mL | |
| 10 mM | 0.2632 mL | 1.3162 mL | 2.6325 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
